of predicted remains quite constant at around 70%. There is an increase in recording of co-morbidities from around 5% in young patients to around 20% in the very elderly. There is a clear and dramatic fall in a number of measures of process and treatment such as histological confirmation rate, anti-cancer treatment, and chemotherapy use beginning around the 7th decade of life. The histological confirmation rate falls from 75% at age 65 to 40% at age 85dthe corresponding rates for specific anti-cancer therapy are 65% and 25%. More concerning is the finding that these variations persist when corrected for PS and co-morbidities (see Abstract P215 Figure  1 ), with treatment rates falling from 50% to 4%.
Introduction Over-representation of women, more advanced disease staging at presentation, better performance status and similar survival figures have been noticed in younger (<50 years) lung cancer patients as compared to the general patient population with the disease. Objective A retrospective study (December 2009 ) was done to derive clinicopathological data from young lung cancer patients treated in our hospital in the last 5 years. We also compared our findings with National Lung Cancer Audit (NLCA), 2007 in the UK. The NLCA data were considered as a reflector of the patients from all age groups. Findings 28 patients were identified for the study. Median age was 48 years (37e50). 15(54%) were female. 75% had WHO performance status (PS)1 in patients with documented PS. 43% had family history of lung cancer. 89% were current smoker. Histology was achieved in 89%. 68% had non small cell carcinoma (NSCLC) including 39% adeno carcinoma, 24% had small cell carcinoma; 2 had carcinoid. 55% of histology proven NSCLC had stage 4 disease at presentation. 86% had some form of treatment (surgery, chemotherapy or radiotherapy). 5(18%) had resection. Survival related data are presented here:
Median survival (days) 1 year survival rate (%) Aim To examine trends in female lung cancer incidence. Introduction Lung cancer incidence in men has been decreasing for the past 2e3 decades, while for females it has increased. Furthermore, to achieve the national cancer mortality target reduction, it is essential that lung cancer incidence reduces as this is a major contributor to the mortality target. Mortality trends closely mirror that of incidence due to the poor prognosis of lung cancer. Introduction and Objectives It is believed by some that endobronchial ultrasound (EBUS) will render conventional transbronchial needle aspiration (cTBNA) obsolete. We sought to explore this question. Methods Data on both conventional (n¼33) and a randomly selected equal number of EBUS-guided TBNA (n¼33), performed to biopsy mediastinal lymph nodes (LN), between August 2008 and May 2010, were extracted from a prospective database of bronchoscopy procedures. Measured variables were age, sex, sampled LN stations and sizes, sample results and final diagnoses for LN and underlying patient diagnosis. Results Thirty-eight LN from 4 different LN stations in the cTBNA group and 46 LN from 5 different LN stations in the EBUS group were sampled. LN were significantly larger in the cTBNA group (median 2.65 cm, range 0.90e7.00 cm) compared to the EBUS-TBNA group (median 1.45 cm, range 0.60e3.00 cm; p<0.001). Accurate diagnoses were obtained in 29/33 (88%) cTBNA cases and 26/33 (79%) EBUS-TBNA (p¼0.51, Fisher's exact test). cTBNA confirmed 23 lung cancers, 1 lymphoma, 3 benign conditions and 2 true negative cases confirmed surgically. Four false negative LN samples were diagnosed with lung cancer (n¼3) and sarcoidosis (n¼1) by other methods. EBUS-TBNA provided an accurate diagnosis in 26 patients (lung cancer, n¼14; other malignancy, n¼2; benign cases, n¼7; true negative, n¼3). Five false negative cases were subsequently diagnosed with lymphoma (n¼1), lung cancer (n¼3) and other malignancy (n¼1). One non-diagnostic sample without further diagnostic clarification was considered false negative. A further sample with possible malignant cell contamination was considered false positive. Discussion In a centre with access to both techniques, selected patients with mediastinal or hilar lymphadenopathy can be investigated with cTBNA without compromising diagnostic accuracy. Across the UK, cTBNA is potentially widely available, and requires minimal capital investment compared to EBUS-TBNA. We believe that cTBNA remains an attractive first-line diagnostic procedure for chest physicians.
Introduction Intra-thoracic lymphadenopathy is commonly observed in patients infected with HIV. The broad range of aetiologies and the non-specific clinical picture constitute a diagnostic challenge which has not been previously addressed. Therefore we aimed to identify the causes of mediastinal lymphadenopathy in HIV infected patients presenting to our specialist unit and to characterise their mode of diagnosis. Methods We conducted a retrospective analytical cohort study of HIV positive patients who underwent CT scanning of the chest between January 2004 and December 2008. Each patient was followed clinically for at least 12 months. Results 234 consecutive patients underwent chest CT in the study period. Employing the conventional CT cut-off for significant lymphadenopathy of 10 mm in short-axis, mediastinal lymphadenopathy was present in 49 (21%) patients. In these 49 patients, the mean age was 40 (range 19e69) years. 43 patients were male and 24 of the male patients were homosexual. 25 (51%) of patients were receiving antiretroviral therapy and 24 patients had a CD4 lymphocyte count below 250 cells 310 6 /l. A specific diagnosis was made in 42 cases. Lymphoma was the most common diagnosis with 9 cases, followed by TB with seven cases. Six patients had reactive lymphadenopathy secondary to pneumonia. There were four cases of Castleman's disease, four of malignancy and three of non-
